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Specificity Evaluation and Disease 
Monitoring in Arthritis Imaging 
with Complement Receptor of 
the Ig superfamily targeting 
Nanobodies
Fang Zheng1,2,3, Harris Perlman4, Patrick Matthys5, Yurong Wen6, Tony Lahoutte7,8, 
Serge Muyldermans2, Shemin Lu1, Patrick De Baetselier2,3, Steve Schoonooghe2,3,*, 
Nick Devoogdt2,6,* & Geert Raes2,3,*
Single-photon emission computed tomography combined with micro-CT (SPECT/μCT) imaging using 
Nanobodies against complement receptor of the Ig superfamily (CRIg), found on tissue macrophages 
such as synovial macrophages, has promising potential to visualize joint inflammation in experimental 
arthritis. Here, we further addressed the specificity and assessed the potential for arthritis monitoring. 
Signals obtained with 99mTc-labelled NbV4m119 Nanobody were compared in joints of wild type (WT) 
versus CRIg−/− mice with collagen-induced arthritis (CIA) or K/BxN serum transfer-induced arthritis 
(STIA). In addition, SPECT/μCT imaging was used to investigate arthritis development in STIA and in 
CIA under dexamethasone treatment. 99mTc-NbV4m119 accumulated in inflamed joints of WT, but 
not CRIg−/− mice with CIA and STIA. Development and spontaneous recovery of symptoms in STIA 
was reflected in initially increased and subsequently reduced joint accumulation of 99mTc-NbV4m119. 
Dexamethasone treatment of CIA mice reduced 99mTc-NbV4m119 accumulation as compared to 
saline control in most joints except knees. SPECT/μCT imaging with 99mTc-NbV4m119 allows specific 
assessment of inflammation in different arthritis models and provides complementary information 
to clinical scoring for quantitatively and non-invasively monitoring the pathological process and the 
efficacy of arthritis treatment.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory disease of the joints, featuring a mixed mono-
nuclear and granulocytic cellular infiltration in the inflamed joints1. Over the past years, RA treatment has shifted 
from controlling symptoms with non-steroidal anti-inflammatory drugs and glucocorticoids such as dexameth-
asone, to controlling the disease process with anti-proliferative or cytotoxic drugs like methotrexate, alone or in 
combination with biologics2,3.
Rodent arthritis models have contributed greatly to the overall knowledge of RA and allow preclinical assess-
ment of novel diagnostic and therapeutic interventions3. Type II collagen induced arthritis in DBA/1 mice 
(CIA) represents the current gold standard and has been used extensively for evaluation of novel therapies3. CIA 
requires specific disease-susceptible inbred mouse strains (DBA/1 and B10.RIII) and places a heavy emphasis on 
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the early inductive phase of disease4. However, most transgenic and knockout strains of mice are in a C57BL/6J 
background (H-2b), which is regarded to be relatively resistant to arthritis induction5. In this context, it has been 
reported that C57BL/6J mice are indeed susceptible to arthritis induced by chicken type II collagen with a modi-
fied immunization protocol. The development of collagen induced arthritis is associated with a very strong T cell 
response that remains elevated for up to 3 months post-immunization6. KRN mice expressing the KRN transgenic 
T cell receptor and MHC class II molecule Ag7 develop severe inflammatory arthritis7. Transfer of arthritogenic 
serum of KRN and nonobese diabetic (K/BxN) mice leads to induction of robust and reproducible disease in 
several mouse strains (K/BxN serum-transfer-induced arthritis [STIA])8. Interestingly, the sterile inflammatory 
arthritis of STIA is transient, often spontaneously resolving after 15–30 days. Similar to human arthritis, STIA fea-
tures high expression of pathogenic autoantibodies to glucose-6-phosphate isomerase (GPI), making this model 
ideal for the identification of the effector pathways involved in the arthritis process9.
Standard non-invasive readouts of disease severity such as paw thickness/volume or clinical scores mainly 
emphasize the oedema component of arthritic disease10. Other non-invasive readouts to monitor disease evo-
lution or treatment efficacy, such as near-infrared, PET or SPECT imaging and scintigraphy, possibly combined 
with anatomical imaging techniques such as X-ray, ultrasonography and magnetic resonance imaging, can pro-
vide information on underlying molecular and cellular inflammatory processes as well as bone destruction. 
Tracers used for molecular arthritis imaging include 18F-fluoro-2-deoxy-D-glucose for visualizing glucose metab-
olism and 99mTc-methylenediphosphonate for monitoring bone turnover11. Various stroma-targeting tracers 
have been described for imaging arthritic synovitis, including 99mTc-anti-E-selectin-Fab for targeting activated 
endothelium12, radiolabelled antibodies targeting fibroblast activation protein for detection of fibrobolast-like 
synoviocytes13 or probes targeting activated macrophages such as 18F-polyethyleneglycol-folate14,15 or 
111In-anti-F4/80-A3-116. In addition, radiolabeled biologicals such as anti-CD3, anti-CD4, anti-CD20 and 
anti-TNF have been evaluated for imaging RA13. As new tools being introduced in this field, Nanobodies are 
tracers combining the specificity of antibodies with the pharmacokinetics of small molecules, thus yielding 
high contract images within hours after inoculation17. In a preclinical setting, Nanobodies allow convenient 
SPECT imaging after standard tricarbonyl-chemistry-based labelling with 99mTc on their carboxy-terminal 
hexahistidine-tag18, distant from the antigen-binding site and thus not interfering with antigen recognition19.
In an approach of targeting markers expressed on macrophages for non-invasive inflammation tracking, we 
reported before that radiolabelled Nanobodies targeting the macrophage mannose receptor (NbMMR), initially 
described as effective probes for in vivo imaging of tumor-associated macrophages in hypoxic tumor areas20,21, 
also accumulate in joints of CIA mice22. Similarly, joint accumulation of the anti-CRIg Nanobody NbV4m119, 
as determined via SPECT/μ CT imaging and quantification of radioactivity in dissected joints, correlates with 
arthritic scores and reflects disease severity over a range of scores in different joints23. Whereas osteoclasts and 
macrophages express similar levels of MMR22, CRIg is readily detected on macrophages but not osteoclasts 
(data not shown). Immunofluorescence microscopy has revealed that NbV4m119 specifically targets a subset of 
CD68-positive macrophages in synovium of DBA/1 CIA mice23. In line with a lower signal in non-arthritic joints, 
and thus a higher contrast for NbV4m119 as compared to NbMMR, accumulation of 99mTc-NbV4m119 in knees 
of mice developing CIA could even be detected before the onset of macroscopic clinical symptoms.
In concordance with CRIg expression on tissue macrophages such as Kupffer cells, 99mTc-NbV4m119 uptake 
in the liver was shown to be higher as compared to a non-targeting control Nanobody in WT but not CRIg−/− 
C57BL/6J mice23. In the current study, we further confirmed the specificity of CRIg targeting by NbV4m119 in 
arthritic joints of WT versus CRIg−/− C57BL/6J CIA mice. In addition, STIA was induced through transfer of 
arthritogenic serum of K/BxN mice, progeny of KRN mice, transgenic for a T cell receptor recognizing an epitope 
of bovine RNase, and nonobese diabetic mice7,8. Interestingly, the sterile inflammatory arthritis of STIA is tran-
sient, spontaneously resolving after 15–30 days9, thus allowing assessment of 99mTc-NbV4m119-based monitor-
ing of the onset, development and recovery of arthritis symptoms of C57BL/6J STIA mice. Finally, we also used 
99mTc-NbV4m119 to monitor dexamethasone treatment effects in DBA/1 CIA mice.
Results
Immunofluorescence microscopy to assess macrophage-specific NbV4m119 targeting in joints 
of collagen-induced arthritis mice. As a first step in addressing the target specificity at the level of the 
cell-type expressing CRIg that is being targeted by the NbV4m119, CIA was induced in DBA/1 mice and immu-
nofluorescence microscopy was performed on tissue sections of decalcified ankles exhibiting different arthritic 
scores. Especially in sections of ankles exhibiting higher arthritic scores, staining by the NbV4m119 could be 
detected (see Supplementary Fig. S0). Moreover, the staining pattern of NbV4m119 overlapped with that one 
of an antibody targeting the macrophage marker F4/80, indicating that NbV4m119 is indeed binding to mac-
rophages in the arthritic joints.
Specificity of NbV4m119 targeting CRIg in C57BL/6J mice with CIA. Another approach to assess 
specificity of targeting, is to compare targeting in WT versus CRIg−/− mice. Since CRIg−/− mice are not available 
in the DBA/1 background and C57BL/6J mice are relatively resistant to CIA5, we used a modified immunization 
protocol to induce CIA in WT and CRIg−/− C57BL/6J mice (Fig. 1a). Yet even when using this protocol, both 
WT and CRIg−/− C57BL/6J mice showed a low disease incidence (2 out of 7 mice developing symptoms in each 
group) as evaluated in two separate experiments and in fact, arthritic scores of individual paws tended to be 
even lower in CRIg−/− C57BL/6J as compared to WT C57BL/6J mice (see Supplementary Fig. S1a). As depicted 
in the experimental time lines in Fig. 1a, imaging using 99mTc-NbV4m119 was performed at day 34 in the four 
symptomatic mice and four asymptomatic mice (two WT and two CRIg−/− C57BL/6J mice). As had been doc-
umented and quantified before23, 99mTc-NbV4m119 targeted CRIg specifically in liver of naïve and arthritic WT 
mice, but not in CRIg−/− mice (see whole body images in Supplementary Fig. S1b). Signals that were detected for 
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99mTc-NbV4m119 in the kidneys and the bladder were also observed for a control, non-targeting 99mTc-NbBCII10 
and are not attributable to specific targeting, but to the fast filtration of unbound Nanobody from the blood-
stream through the renal route. As far as the uptake in joints is concerned, in WT mice 99mTc-NbV4m119 showed 
higher uptake in inflamed joints as compared to asymptomatic joints (Fig. 1b, left of the dotted line). In contrast, 
inflamed joints of CRIg−/− C57BL/6J mice (score 3 as compared to score 0) only showed a slightly higher uptake 
of 99mTc-NbV4m119 that may be due to joint oedema (Fig. 1b, left of the dotted line). Moreover, when comparing 
joints with the same arthritic score 3, 99mTc-NbV4m119 signals were much higher in WT versus CRIg−/− mice, 
indicating the antigen-specificity of these signals.
A reduced accumulation of NbV4m119 in CRIg−/− mice as compared to WT mice could not only be due to 
the absence of CRIg as a target in these mice, but could also be related to a functional effect of the absence of CRIg 
on the intensity of the arthritic inflammation or oedema that would affect the tissue penetration of Nanobodies 
in general, independent of the target specificity. To exclude this possibility we also included NbMMR in this 
study as a Nanobody of which the target is still expected to be present in CRIg−/− mice. Thereby, the uptake of 
99mTc-NbMMR was quantified via SPECT/μ CT imaging in the same mice at day 38 post immunization (see exper-
imental time lines in Fig. 1a). As reported before22, NbMMR targets MMR in several organs and tissues, including 
myocardium, bone marrow, spleen and liver, but also accumulates in joints of CIA mice (see Supplementary 
Fig. S1b). Notably, and in contrast to the results obtained with 99mTc-NbV4m119, uptake of 99mTc-NbMMR was 
enhanced in inflamed versus asymptomatic joints in both WT mice and CRIg−/− C57BL/6J mice (Fig. 1b, right 
of the dotted line), arguing against a reduced joint inflammation in CRIg−/− CIA mice being the cause for the 
lower 99mTc-NbV4m119 uptake. Furthermore, reconstructed SPECT/μ CT images revealed hot spots of radioac-
tive signals only in symptomatic wrists in WT mice injected with 99mTc-NbV4m119 and WT or CRIg−/− mice 
injected with 99mTc-NbMMR, but not in 99mTc-NbV4m119 injected CRIg−/− mice or in mice injected with a 
control, non-targeting NbBCII10 (at day 42 post immunization), confirming specificity of the 99mTc-NbV4m119 
Figure 1. SPECT/CT quantification and imaging of 99mTc-NbV4m119, 99mTc-NbMMR or 99mTc-
NbBCII10 accumulation in WT and CRIg−/− (KO) C57BL/6J mice with CIA after the onset of the 
arthritis symptoms. (a) Experimental timelines for C57BL/6J mice with CIA; IFA = Incomplete Freund’s 
Adjuvant; M.t = Mycobacterium tuberculosis strain H37RA; Sac = mice were sacrificed. SPECT/micro-CT 
imaging was performed 3 h post intravenous injection of 99mTc-labeled NbV4m119, NbMMR or NbBCII10. 
(b) Signals obtained in the joints with score 3 and joints with score 0 were grouped in four symptomatic and 
four asymptomatic mice (two WT and two KO mice in each group). Data are expressed as mean values of % 
of injected activity (%IA) of 99mTc-Nanobodies obtained from the limbs (front paws, metatarsal joints and 
ankles). **p < 0.01 and ***p < 0.001. (c) Representative SPECT/μ CT image of front paws in CIA mice, 3 h post 
injection with 99mTc-labeled NbV4m119, NbMMR or NbBCII10. Clinical scores are indicated next to each joint. 
Representative images of 1 mouse per group are shown using National Institutes of Health color scale and are 
scaled to maximum in the whole image. The data are representative of two independent experiments.
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signals (see cropped images focusing on front paws in Fig. 1c). Similar conclusions were obtained for signals in 
other joints such as ankles or knees (see whole body images in Supplementary Fig. S1c).
Specificity of NbV4m119 targeting in STIA C57BL/6J mice. Next, STIA was induced in C57BL/6J 
mice, whereby 8 days later one group of mice was used for imaging using 99mTc-NbV4m119 and another group of 
mice was used for imaging using 99mTc-NbMMR (see experimental time lines in Fig. 2a). Symptoms were mainly 
observed in the ankles, whereas some of the wrists seemed to remain asymptomatic at day 8 (see Supplementary 
Fig. S2a,S2b). For imaging with 99mTc-NbV4m119, 4 WT and 4 CRIg−/− serum injected mice at day 8 (all mice 
developing symptoms) were compared to 3 WT and 3 KO naive mice. The mean levels of 99mTc-NbV4m119 
uptake in wrists and ankles of WT arthritic mice, which developed symptoms, were higher as compared to naive 
WT and CRIg−/− mice (Fig. 2a). The signal of 99mTc-NbV4m119 uptake in symptomatic wrists and ankles of 
CRIg−/− mice was not different as compared to non-symptomatic joints or naive joints in CRIg−/− mice. The same 
conclusions were obtained via measurement of radioactivity in dissected joints of euthanized mice as compared 
to quantification of the imaging data (see Supplementary Fig. S2c). Representative images cropped to focus on 
hind legs are shown in Fig. 2c, and whole body images including also front paws are shown in Supplementary Fig. 
S2e, highlighting focal signals of 99mTc-NbV4m119 uptake in ankles of arthritic WT mice, but not of naïve WT or 
arthritic or naïve CRIg−/− mice (Fig. 2c).
A different set of mice was imaged with the 99mTc-NbMMR, whereby 4 WT and 4 CRIg−/− serum injected 
mice at day 8 were compared to 3 WT and 3 CRIg−/− naive mice. The wrists and ankles showed significantly 
higher signals in symptomatic WT mice (score > 0) as compared to naive WT mice (Fig. 2b,c and Supplementary 
Fig. S2d). Of note, in this experiment the symptomatic CRIg−/− mice had a lower score in ankles than the WT 
mice, suggesting CRIg deficiency may (variably) affect arthritis development in these mice (Supplementary Fig. 
S2b). Accordingly, 99mTc-NbMMR uptake was significantly higher in the ankle joints but not in wrists of sympto-
matic WT as compared to symptomatic CRIg−/− mice. Yet, in contrast to the results obtained with NbV4m119, 
NbMMR uptake in CRIg−/− mice was increased in ankles and wrists of symptomatic mice as compared to naive 
Figure 2. In vivo SPECT/CT imaging with an anti-CRIg tracer (NbV4m119) or an anti-MMR tracer 
in arthritic joints of C57BL/6J WT and CRIg−/− (KO) mice with STIA. Experimental timelines and 
quantification of tracer accumulation in wrist and ankle joints of C57BL/6J mice with STIA which were injected 
with KBxN serum and monitored via SPECT/micro-CT imaging using 99mTc-NbV4m119 (a) or 99mTc-NbMMR 
(b) at day 8 post serum transfer. For each tracer, 4 KO and WT mice were injected with serum and 3 naïve 
KO and WT mice were used as control. Imaging & Sac = mice were imaged and sacrificed. The % of injected 
activity (%IA) was quantified for the wrist or ankle area in SPECT imaging (mean ± SEM, ***p < 0.001, ns: not 
significant). Naive: naive mice without serum injection; Score > 0: the ankles with arthritis score 1, 2 or 3. (c) 
Representative SPECT/μ CT image of STIA C57BL/6J mice, 3 h post injection with 99mTc-labeled NbV4m119 or 
99mTc-labeled NbMMR. Clinical scores are indicated next to each joint. Representative images of ankles in 1 out 
of 4 mice per group are shown using National Institutes of Health color scale and are scaled to maximum in the 
whole image.
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mice (Fig. 2b,c and Supplementary Fig. S2d,S2f), indicating that the lack of accumulation of 99mTc-NbV4m119 
in ankles and wrists of symptomatic versus asymptomatic CRIg−/− mice truly reflects the absence of specific 
targeting to inflamed joints in the KO mice rather than merely reduced inflammation in joints of CRIg−/− mice.
Using 99mTc-NbV4m119 for monitoring arthritis progression in STIA. Next, we evaluated 
99mTc-NbV4m119 for monitoring the initial induction and later recovery of RA symptoms in STIA. 12 C57BL/6J 
mice were injected with K/BxN serum on day 0. Mice were imaged with 99mTc-NbV4m119 at 2 days (onset of 
RA), 8 days (peak of RA) and 15 days (recovering phase of RA) after initial immunization (Fig. 3a). The scores of 
these mice increased from day 2 to day 8 and subsequently decreased after 15 days (Fig. 3b and Supplementary 
Fig. S3a). Significant 99mTc-NbV4m119 uptake was mainly observed in inflamed joints in hind legs (Fig. 3c) and 
in front paws (see Supplementary Fig. S3b) of arthritic mice. When assessing probe accumulation in individual 
wrists and ankles, 99mTc-NbV4m119 uptake at day 8 was significantly increased as compared to day 2 (Fig. 3d). 
In line with the observation that the symptoms were reduced in mice beyond day 8, the 99mTc-NbV4m119 accu-
mulation in the wrists and ankles significantly decreased at day 15 as compared to day 8 (Fig. 3d). These results 
demonstrate that 99mTc-NbV4m119 can sense the CRIg level in vivo from the onset, peak and recovery of arthritis.
Monitoring the effect of dexamethasone therapy for RA using 99mTc-NbV4m119 in CIA DBA/1 
mice. Finally, we evaluated the use of 99mTc-NbV4m119 for monitoring the effects of therapeutic intervention. 
In order to obtain a maximum sensitivity for the effect of the therapeutic treatment, we used the gold-standard 
model of CIA in arthritis-sensitive DBA/1 mice for these experiments. Two groups of mice (n = 10) were com-
pared to allow monitoring the effect of the dexamethasone treatment: one group received dexamethasone i.p. 
daily 28 days after arthritis-induction and the second group was injected with saline as control. Each group 
was imaged with 99mTc-NbV4m119 at day 28 (before treatment) and day 42 (after treatment) after initial 
immunization (Fig. 4a). Before the start of treatment at day 28, mice in both groups had an average cumula-
tive arthritic score of 4. In contrast to the saline injected group, the scores of the mice in the dexamethasone 
treated group decreased to nearly baseline treatment till day 40. We also noticed that as soon as the dexameth-
asone treatment stopped on day 41, the arthritis scores of this group rebounded again on day 42 (Fig. 4b). The 
total 99mTc-NbV4m119 accumulation in four limbs of mice in the dexamethasone treated group (at 42 days post 
Figure 3. In vivo SPECT/CT imaging with an anti-CRIg tracer for monitoring arthritis recovery in STIA 
C57BL/6J mice. (a) Experimental timelines for 12 WT mice injected with KBxN serum and imaged at day 2, 
day 8 and day 15 post serum transfer. Imaging = SPECT/μ CT imaging. (b) The clinical arthritic scores (additive 
scores for all 4 paws of each mouse, expressed as group mean ± SEM) were measured at day 2, day 8 and day 15 
after immunization. (c) Representative SPECT/μ CT image of ankles in STIA serum transfer arthritis mice, 3 h 
post injection with 99mTc-labeled NbV4m119. The same arthritic mice displaying symptoms of arthritis showed 
specific uptake of 99mTc-labeled NbV4m119 in inflamed joints on day 2, day 8 and day 15 post serum injection. 
Clinical scores are indicated next to each joint. Representative images of 1 out of 12 mice per group are shown 
using National Institutes of Health color scale and are scaled to maximum in whole image. (d) Uptake of 99mTc-
NbV4m119 in individual wrists and ankles of mice. The % of injected activity (%IA) was quantified for the wrist 
area. score 0: the wrists with score 0; S > 0: the wrists with arthritis score 1, 2 or 3. The % of injected activity 
(%IA) was quantified for the ankle area. (mean ± SEM, *P < 0.05, **P < 0.01, *** P< 0.001, ns: not significant).
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immunization) was significantly lower than in the saline treated group, which correlated with decreasing clinical 
scores (Fig. 4c,d). Similar conclusions were obtained in ankles, but no significant difference was detected among 
knees of dexamethasone treated and control mice. Hot spots of 99mTc-NbV4m119 accumulation were observed 
in knees of both groups of mice (see Supplementary Fig. S4). Notably, in all joints, the recorded imaging readout 
values in the dexamethasone injected group at day 42 remained at least as high as those recorded at day 28 (i.e. 
before the onset of therapy) (Fig. 4c).
Discussion
Molecular imaging of arthritis, which includes anatomical imaging techniques such as ultrasonography and MRI 
or molecular imaging such as optical imaging or nuclear imaging, will improve the understanding of the patho-
genesis and development of the disease. MRI imaging produces anatomically detailed images of cartilage, ten-
dons, synovial membrane and bone which ultrasonography could not penetrate11. It provides a higher contrast 
resolution, allowing detection of synovial hyperplasia, cartilage and bone degradation, inflammation and oste-
itis and is able to show signs of early arthritis in patients24. Molecular imaging can provide molecular informa-
tion on the underlying biochemical and inflammatory processes, that is complementary to anatomical imaging. 
Development of metal plasmonic nanoparticles for MRI25 allows using MRI also for molecular imaging in addi-
tion to its use for anatomical imaging. Other molecular probes being developed for molecular arthritis imaging 
include fluorescence and near-infrared labelled probes26 for optical imaging or radioisotopes labelled probes for 
scintigraphy, PET or SPECT14. Nuclear imaging techniques generate deeper tissue penetration and lower back-
ground than optical imaging techniques and are more sensitive than structural imaging11. In the current study, 
we built on previous results obtained with NbV4m119 as a probe for molecular imaging of arthritic inflamma-
tion23. Despite the low incidence of arthritis in the CIA model in C57BL/6J mice, we obtained antigen-specific 
99mTc-NbV4m119 signals in arthritic WT mice but not in arthritic CRIg−/− mice. Also in the STIA model, which 
Figure 4. Monitoring the clinical scores and uptake of 99mTc-NbV4m119 in the four limbs of DBA/1 mice 
with CIA following dexamethasone therapy. (a) Experimental timelines for the CIA therapy monitoring 
experiment; CFA = Complete Freund’s Adjuvant; IFA = Incomplete Freund’s Adjuvant; Imaging = SPECT/μ CT 
imaging; Sac = mice were sacrificed. Mice (n = 10) were immunized with type II collagen in complete Freund’s 
adjuvant. The treatments were started at 28 days and finished at 41 days after initial immunization. Treatments 
consisted of daily i.p. injection with 100 μ l saline control or 0.25 mg/kg dexamethasone. (b) The clinical additive 
scores of the RA mice were measured until 42 days after immunization. *p < 0.05, **p < 0.01, and ***p < 0.001. 
(c) SPECT/CT image quantification of 99mTc-NbV4m119 in all 4 limbs of CIA DBA/1 mice (sum of ankles 
and front paws) at 28 days and 42 days after immunization were quantified as %IA. Data are expressed as 
mean ± SEM. ns: not significant, **p < 0.01. (d) Representative SPECT/μ CT image of front paws in CIA DBA/1 
mice, 3 h post injection with 99mTc-labeled NbV4m119. The same arthritic mice displaying symptoms of arthritis 
showed specific uptake of 99mTc-labeled NbV4m119 in front paws on 28 days and 42 days post serum injection. 
Clinical scores are indicated next to each joint. Representative images of front paws in 1 out of 10 per group 
CIA DBA/1 mice are shown using National Institutes of Health color scale and are scaled to maximum in whole 
image.
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is readily inducible in C57BL/6J mice, 99mTc-NbV4m119 specifically detected the inflamed lesions in the arthritic 
WT mice but not in the CRIg−/− mice. Throughout these different experiments in the CIA and STIA models, 
hot spots of 99mTc-NbV4m119 accumulation in arthritic joints of CRIg−/− mice were never detected. Moreover, 
sustained joint accumulation of 99mTc-NbMMR in CRIg−/− mice indicates that the impaired accumulation of 
99mTc-NbV4m119 in symptomatic CRIg−/− mice truly reflects the absence of specific targeting in CRIg−/− mice, 
rather than reduced joint inflammation.
99mTc-NbV4m119 signals provide a quantitative read-out for disease development and resolution in the STIA 
model. The detection of hot spots of NbV4m119 signal in some of the score 0 joints at day 2, suggests that the 
in vivo imaging is more sensitive than the classic scoring system. These findings offer perspectives for monitoring 
disease evolution, either spontaneous or under therapy, provided that baselines can be established allowing com-
parison of the obtained signals. Increased resolution when switching from SPECT to PET imaging and increased 
joint size in humans as compared to rodents, thereby hold potential for increased contrast upon clinical transla-
tion of such inflammation imaging.
Non-invasive imaging can monitor the same animal at different time points before or after the onset of arthritis, 
allowing to follow up a therapy or treatment. MRI-based outcome measures have recently been adopted by 
pharma companies for clinical trial research to measure clinical trial outcome of therapy such as anti-TNF agents, 
including adalimumab, infliximab, etanercept and golimumab. These enable earlier assessment of drug efficacy 
than radiographic outcomes27. In a recent study using 111In-labelled antibodies targeting fibroblast activation pro-
tein, macrophages and integrin α vβ 3, decreased joint uptake of tracers was observed in arthritic mice undergoing 
etanercept treatment28. In the current study using 99mTc-NbV4m119 in CIA DBA/1 mice receiving dexametha-
sone as therapy, the recorded signals at day 42 were lower in the dexamethasone injected group as compared to 
the saline control group, but remained at least as high as those recorded at day 28 (i.e. before the onset of therapy). 
At the level of the knees, wherein 99mTc-NbV4m119-based imaging is a sensitive indicator of inflammation29, 
similar signals were even detected in the dexamethasone treated group as in the control group. These data are in 
line with the observation that the clinical scores rose immediately as soon as dexamethasone treatment stopped, 
confirming that dexamethasone is better at providing symptom relief than at altering disease progression30 and 
indicating that SPECT/μ CT imaging can indeed provide complementary molecular information on the effect of 
the therapy on the underlying disease pathology in the various joints as compared to the clinical score.
Our studies have confirmed that Nanobodies targeting CRIg constitute a specific tool for non-invasive 
SPECT/CT imaging as a way of assessing inflammation in arthritis models in vivo. Moreover, the monitoring 
studies indicate that imaging arthritic mice using 99mTc-NbV4m119 appears to serve as a non-invasive means for 
tracing disease evolution and response to therapy, providing complementary and more sensitive information as 
compared to paw swelling and clinical scoring.
Materials and Methods
Ethical approval. Animal studies were performed according to the European Community Council Directive 
2010/63/EU and were approved by our university’s Ethical Committee for Animal Experiments (Approval N°12-
220-6; 24/09/2012).
Mice. Male C57BL/6J (8–12 week-old) and DBA/1 mice (8 week-old) were purchased from Janvier Sas. 
CRIg−/− mice (C57BL/6J background) were generously provided by Genentech (San Francisco, CA).
Arthritis models. CIA was induced in WT and CRIg−/− C57BL/6J male mice using a modified immuni-
zation involving two 21-day-separated subcutaneous injections of 100 μ L of 4 mg/mL chicken collagen type II 
(Sigma-Aldrich) in acetic acid, emulsified in incomplete Freund’s adjuvant with added 3.3 mg/mL heat-killed 
Mycobacterium tuberculosis strain H37RA (Difco Laboratories), at two sites (the base of the tail and a slightly more 
anterior location) after anesthesia. Each limb was scored for severity of arthritis for CIA as follows: 0 = normal; 
1 = redness/swelling of one joint; 2 = redness/swelling of more than one joint; 3 = swelling of entire paw; 
4 = ankylosis and/or deformity. For dexamethasone treatment efficacy monitoring and immunofluorescence 
microscopy, cohorts of DBA/1 mice were used for CIA induction as described23 and were treated daily with i.p. 
0.25 mg/kg dexamethasone in 100 μ L saline or saline control from day 28 to day 41.
STIA mice were sensitized via an i.v. injection in the tail of C57BL/6J mice with 60 μ L of arthritogenic serum 
from K/BxN mice as described8. All paws were assigned a score for inflammation in STIA on a scale of 0 to 3: 
1 = mild swelling of the ankle insufficient to reverse the normal V shape of the foot; 2 = swelling sufficient to 
make the ankle and midfoot approximately equal in thickness to the forefoot; 3 = reversal of the normal V shape 
of the foot. The thickness of the ankles and the wrists were monitored using a calliper across the ankle or wrist 
joint at the widest point.
Nanobodies. Nanobodies against CRIg (NbV4m119), the β -lactamase BCII enzyme of Bacillus cereus 
(NbBCII10) and MMR (NbMMR) were generated as described19,22,23. For 99mTc labelling, the Nanobodies were 
subcloned into the pHEN6c vector introducing a hexahistidine-tag. All Nanobodies were produced in, and puri-
fied from, the periplasm of Escherichia coli WK6 cells.
99mTc-Nanobody labelling and pinhole SPECT/μCT analysis. Nanobodies were labelled with 99mTc 
via the hexahistidine tag, purified via NAP-5 column (Sephadex G-25, GE Healthcare) and 0,22 μ m membrane 
filtered as described18. Radiochemical purity was determined using instant thin-layer chromatography (Pall 
Corp., Life Sciences) in acetone solvent, revealing the amount of Nb-complexed and unincorporated 99mTc at 
the application and the solvent front, respectively18. 52.8 ± 0.01 MBq of 99mTc-Nbs activity in 80–100 μ L (at 192 
MBq/nmol) was injected. 3 h post injection, anesthetized mice were imaged using μ CT (Skyscan 1178; Skyscan) 
followed by pinhole SPECT (e.cam180; Siemens Medical Solutions) as described23. Images were reconstructed 
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as described31, using an iterative reconstruction algorithm and corrected for attenuation and scatter. Micro-CT 
images were reconstructed using filtered backprojection (NRecon; SkyScan). Images were viewed and analyzed 
using AMIDE: A Medical Image Data Examiner software32. A calibration factor, obtained by SPECT image anal-
yses of syringes with known activities, is used to convert SPECT image pixels to radioactivity levels. Regions of 
interest were drawn, recorded amounts of radioactivity in these regions were divided by the amount of injected 
activity (corrected for decay) and expressed as percentage of injected activity (% IA).
To determine biodistribution ex vivo, mice were sacrificed and tissues were dissected and weighed, and their 
radioactivity content was measured using an automated γ -counter (Cobra II Inspector 5003; Canberra-Packard, 
Schwadorf, Austria). Organ uptake was calculated as the percentage of injected activity per gram (% IA/g) and 
corrected for decay.
SPECT/μCT imaging time lines for the different arthritis models. (1) In vivo imaging monitoring 
the modified CIA model in WT (n = 2) and CRIg−/− (n = 2) C57BL/6J mice. The imaging was performed at day 
34, day 38 and day 42, using 99mTc-NbV4m119, 99mTc-NbMMR, or 99mTc-NbBCII10 respectively. The clinical 
scores of the wrists and ankles were monitored. (2) In vivo imaging monitoring STIA at day 8. WT and CRIg−/− 
C57BL/6J mice (n = 4, 14 weeks old) received the KBxN mouse serum administration. The clinical scores and 
the thickness of the wrists and ankles were monitored at day 8. The arthritic WT and CRIg−/− mice were injected 
with 99mTc-NbV4m119 or 99mTc-NbMMR and imaged by SPECT/CT on day 8 post serum injection. After the 
anesthetized mice were imaged using μ CT followed by pinhole SPECT, mice were sacrificed, wrists and ankles 
were dissected and weighed, and their radioactivity content was measured using an automated γ -counter. (3) 
In vivo imaging monitoring the STIA pathological process. WT C57BL/6J mice (n = 12, 10 weeks old) received 
the KBxN mice serum administration. The clinical scores and the thickness of the wrists and ankles were mon-
itored till day 15. The arthritic WT C57BL/6J mice were injected with 99mTc-NbV4m119 each time and imaged 
by SPECT/CT on day 2 (onset of RA), day 8 (peak of RA) and day 15 (RA partly resolved) post serum injection. 
Anesthetized mice were imaged using μ CT followed by pinhole SPECT. (4) Treatment efficacy monitoring by 
99mTc-NbV4m119. For evaluation of the dexamethasone therapy by imaging, beginning on 28 days after the ini-
tial immunization, cohorts of CIA DBA-1 mice (n = 10) were treated i.p. with dexamethasone (daily) or received 
saline (daily) and served as control. The treatments were finished at day 41. Till day 42, the scores were monitored 
for each mouse every two days. The arthritic mice were injected with 99mTc-NbV4m119 and imaged by SPECT/
CT before (day 28) and after (day 42) the dexamethasone or saline treatments.
Immunofluorescence microscopy. CIA was induced in DBA/1 mice. Mice were sacrificed under anes-
thesia and ankles exhibiting different arthritic scores were removed and fixed in 4% paraformaldehyde solution 
for 24 hours. Ankles were decalcified in 10% EDTA pH 7.4 (Sigma, USA) for 4 weeks (EDTA solution refreshed 
once a week) then embedded in paraffin. 8 μ m sections were prepared from paraffin-embedded tissues. The 
sections were incubated in 1% blocking reagent (Roche) in PBS (1% PBS/BR) containing detection antibodies. 
Anti-F4/80(Cl:A3-1)/Alexa fluor 488 was purchased from AbD Serotec and anti-HA-tag (16B12)/Alexa Fluor 
594 was purchased from Invitrogen. Each section was incubated overnight with 2 μ g of antibody and Nb. Specific 
labelling was detected with anti-HA/Alexa fluor 549 in 1% PBS-BR. Fluoro-Gel II/DAPI (Electron Microscopy 
Sciences) mounted slides were used for fluorescence microscopy with a UPlanFI 10x, 20x or 30x objective on a 
OLYMPUS BX51 microscope with OLYMPUS DP71 CCD and OLYMPUS DP Controller software.
Statistical analysis. Significance analysis of data was conducted using a two-tailed unpaired Student’s T test 
when two groups were analyzed or one-way ANOVA analysis of variance multiple–comparison post-test. Prism 
6.0 (Graphpad software) was used for statistical analyses and graph creation. P-values ≤ 0.05 were considered 
significant.
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